Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

1 Trials

All TrialsPhase 3

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Rintega (rindopepimut) / Celldex

NCT01480479 / 2011-006068-32: Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

	First Interim data from ACT IV trial in frontline GBM [Trial failed]
	May 2016 - May 2016: First Interim data from ACT IV trial in frontline GBM [Trial failed]
	Second interim analysis of P3 ACT IV trial in front-line GBM [Trial failed]
	May 2016 - May 2016: Second interim analysis of P3 ACT IV trial in front-line GBM [Trial failed]
	From ACT IV trial for front-line GBM at SNO 2016 [Trial failed]
	May 2016 - May 2016: From ACT IV trial for front-line GBM at SNO 2016 [Trial failed]
	From ACT IV trial in 1L glioblastoma
	Mar 2016 - Mar 2016: From ACT IV trial in 1L glioblastoma
	Analysis of ACT IV trial for front-line GBM
	Mar 2016 - Mar 2016: Analysis of ACT IV trial for front-line GBM
	Completion of enrollment in P3 ACT IV trial for glioblastoma
	Dec 2014 - Dec 2014: Completion of enrollment in P3 ACT IV trial for glioblastoma
	Interim P2 data
	Nov 2013 - Nov 2013: Interim P2 data
	Global registration in front-line GBM (malignant glioblastoma)
	Nov 2011 - Nov 2011: Global registration in front-line GBM (malignant glioblastoma)
More

Completed

745

US, Canada, Europe, RoW

Rindopepimut (CDX-110) with GM-CSF, CDX-110 with sargramostim (GM-CSF) (Leukine®), Temozolomide, Temodar, Temodal, KLH

Celldex Therapeutics

Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma, Glioblastoma With Oligodendroglial Component

11/16

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites